奥拉帕尼片致肝损伤1例

doi:10.19803/j.1672-8629.2019.12.12

中国药物警戒 ›› 2019, Vol. 16 ›› Issue (12): 762-764.
DOI: 10.19803/j.1672-8629.2019.12.12

奥拉帕尼片致肝损伤1例

徐银莹, 姜孙旻

南京医科大学附属无锡妇幼保健院,江苏无锡 214002

收稿日期:2019-12-18 修回日期:2019-12-18 出版日期:2019-12-15 发布日期:2019-12-18
通讯作者: *姜孙旻,女,硕士,主管药师,临床药学。
作者简介:徐银莹,女,本科,主管药师,临床药学。
基金资助:
无锡市卫计委科研青年项目（Q201603）：; 无锡市卫计委“科教强卫工程”青年医学人才项目（QNRC025）

One Case of Hepatic Dysfunction Induced by Olaparib Tablets

XU Yinying, JIANG Sunmin

The Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University, Wuxi Jiangsu 214002, China

Received:2019-12-18 Revised:2019-12-18 Online:2019-12-15 Published:2019-12-18

摘要/Abstract

中图分类号:

R994.11

徐银莹, 姜孙旻. 奥拉帕尼片致肝损伤1例[J]. 中国药物警戒, 2019, 16(12): 762-764.

XU Yinying, JIANG Sunmin. One Case of Hepatic Dysfunction Induced by Olaparib Tablets[J]. Chinese Journal of Pharmacovigilance, 2019, 16(12): 762-764.

[1] 于乐成, 茅益民, 陈成伟. 药物性肝损伤诊治指南[J].中华肝脏病杂志, 2015, 23(10):1752-1769.
[2] 刘建平, 邢建民. 循证的药品不良反应评价方法[J]. 中国药物警戒, 2010, 7(1):12-15.
[3] Moore Kathleen, Colombo Nicoletta, Scambia Giovanni,et al.Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer[J]. N Engl J Med, 2018, 379(26):2495-2505.
[4] Friedlander Michael, Matulonis Ursula, Gourley Charlie,et al.Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy[J]. Br J Cancer,2018, 119(9):1075-1085.
[5] Moore K N, Monk B J.Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer[J]. Oncologist, 2016, 21(8):954-63.
[6] Pujadelauraine E, Ledermann J A, Selle F, et al.Olaparib tablets as maintenance therapy in patients with platinum-sensitive,relapsed ovarian cancer and a BRCA1/2 mutation(SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(9):1274-1284.
[7] Robson Mark, Im Seock-Ah, Senkus Elżbieta, et al.Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation[J]. N Engl J Med, 2017,377(6): 523-533.
[8] Bang Yung-Jue, Xu Rui-Hua, Chin Keisho, et al.Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(12):1637-1651.
[9] Ledermann Jonathan A, Harter Philipp, Gourley Charlie,et al.Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib main tenance monotherapy: an updated analysis from a randomised,placebo-controlled, double-blind, phase 2 trial[J]. Lancet Oncol, 2016, 17(11): 1579-1589.
[10] Oza Amit M, Cibula David, Benzaquen Ana Oaknin, et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial[J]. Lancet Oncol, 2015, 16(1):87-97.
[11] Kaufman B, Shapirafrommer R, Schmutzler R K, et al.Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation[J]. J Clin Oncol,2015, 33(3):244-50.
[12] Domchek S M, Aghajanian C, Shapira-Frommer R, et al.Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy[J]. Gynecol Oncol,2016, 140(2):199-203.
[13] Liu J F, Barry W T, Birrer M, et al.Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study[J]. Lancet Oncol, 2014, 15(11):1207-1214.
[14] Del Conte G, Sessa C, Von Moos R, et al.Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours[J]. Br J Cancer, 2014, 111(4):651-659.
[15] Balmana J, Tung N M, Isakoff S J, et al.Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors[J]. Ann Oncol, 2014, 25(8):1656-1663.
[16] Choy Edwin, Butrynski James E, Harmon David C, et al.Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy[J].BMC Cancer, 2014, 14(1):1-6.
[17] Ledermann Jonathan, Harter Philipp, Gourley Charlie, et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial[J]. Lancet Oncol, 2014, 15(8):852-861.
[18] Sandhu S K, Omlin A, Hylands L, et al.Poly (ADP-ribose)polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer[J]. Ann Oncol,2013, 24(5):1416-1418.
[19] Samol J, Ranson M, Scott E, et al.Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study[J].Invest New Drugs, 2012, 30(4):1493-1500.
[20] Ledermann J, Harter P, Gourley C, et al.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer[J].N Engl J Med, 2012, 366(15):1382-1392.
[21] Kaye S B, Lubinski J, Matulonis U, et al.Phase II, open-label,randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor,and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer[J]. J Clin Oncol, 2012, 30(4):372-379.
[22] Khan O A, Gore M, Lorigan P, et al.A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436)and dacarbazine in patients with advanced solid tumours[J].Br J Cancer, 2011, 104(5):750-755.
[23] Liu J, Fleming G F, Tolaney S M, et al.A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast cancer[J]. J Clin Oncol, 2011, 29(15):5028-5028.

奥拉帕尼片致肝损伤1例

One Case of Hepatic Dysfunction Induced by Olaparib Tablets

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	孙绮悦, 赵荣华, 郭姗姗, 包蕾, 耿子涵, 李舒冉, 徐英莉, 张敬升, 崔晓兰, 孙静. 羚羊感冒口服液多重药理作用研究[J]. 中国药物警戒, 2024, 21(2): 127-131.
[2]	赵荣华, 孙静, 包蕾, 耿子涵, 陶夏莉, 张敬升, 庞博, 徐英莉, 曹姗, 李舒冉, 郭姗姗, 王道涵, 崔晓兰. 基于免疫调节探讨葛根汤颗粒治疗小鼠病毒性肺炎的作用机制[J]. 中国药物警戒, 2024, 21(2): 132-136.
[3]	包蕾, 耿子涵, 李舒冉, 冀祖恩, 赵荣华, 孙静, 郭姗姗, 崔晓兰. 瞬时受体电位通道在病毒性肺炎发展过程中的关键作用[J]. 中国药物警戒, 2024, 21(2): 137-140.
[4]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[5]	李嘉昕, 刘慧敏, 钱文秀, 马宁, 宋丽丽, 李遇伯. 基于中药系统毒理学数据库的中药致肾毒性及药物规律研究[J]. 中国药物警戒, 2024, 21(2): 173-180.
[6]	范凯凯, 王聪, 刘洪峰, 王西勇. 临床药师对某院丙氨酰谷氨酰胺注射液应用干预分析[J]. 中国药物警戒, 2024, 21(2): 181-184.
[7]	张建, 方慧华. 某院活血化瘀类中药注射剂使用评价标准建立的探索[J]. 中国药物警戒, 2024, 21(2): 185-189.
[8]	王珊, 谢波, 刘慧敏, 李志浩. 基于FAERS数据库对塞来昔布不良事件信号的分析[J]. 中国药物警戒, 2024, 21(2): 190-194.
[9]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[10]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[11]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[12]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[13]	李娜, 郭军, 郭文佳, 吕茵茵, 李彩宏, 牟向东. 奥马珠单抗注射剂治疗哮喘致迟发型皮肤过敏反应1 例分析[J]. 中国药物警戒, 2024, 21(2): 211-212.
[14]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[15]	朱盈, 沈璐, 李岚, 吴建民, 高晓洁. 新法规体系下我国牙膏不良反应监测工作分析与思考[J]. 中国药物警戒, 2024, 21(2): 219-222.